Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The treatment of tricyclic resistant depression is largely empirical because of the lack of clear definition of the term 'resistant depression' and the paucity of controlled trials of this indication. While there is substantial clinical evidence for the efficacy of ECT in tricyclic resistant patients the most established drug treatments are lithium augmentation and monoamine oxidase inhibitor therapy, the latter particularly if the clinical presentation includes features of atypical depression. The combination of neuroleptics and tricyclic treatment is of value in the treatment of depressive psychosis. Several other drug treatments, less well-documented, undoubtedly help some patients. There is a need to establish clinical and biochemical predictors to help identify the likely response of individual patients to particular therapeutic regimes. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

Original publication




Journal article


International Review of Psychiatry

Publication Date





239 - 248